darzalex fda approval history

Darzalex FDA Approval History: A Journey of Medical Innovation in Multiple Myeloma Treatment

darzalex fda approval history is a fascinating tale of scientific advancement and regulatory milestones that have significantly impacted the treatment landscape for multiple myeloma and related blood cancers. Since its initial approval, Darzalex (daratumumab) has transformed from a novel therapeutic option into a cornerstone of multiple myeloma therapy, offering hope to many patients worldwide. Understanding this history not only sheds light on the drug's development but also highlights the evolving nature of cancer treatment and the FDA's role in facilitating access to groundbreaking medicines.

The Origins of Darzalex: From Lab to Clinic

The story of Darzalex begins with its designation as a monoclonal antibody targeting CD38, a protein highly expressed on multiple myeloma cells. Developed by Janssen Pharmaceuticals, Darzalex was designed to harness the immune system to attack malignant plasma cells selectively. Early research demonstrated its potential to improve outcomes in patients with relapsed or refractory multiple myeloma, a patient population with limited treatment options at the time.

The drug's mechanism of action involves multiple pathways, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis induction. This multifaceted approach made Darzalex a promising candidate for FDA evaluation.

Darzalex FDA Approval Milestones

Initial FDA Approval in 2015

The pivotal moment in the darzalex fda approval history came in November 2015, when the U.S. Food and Drug Administration granted accelerated approval for Darzalex. This approval was specifically for patients with multiple myeloma who had received at least three prior therapies, including a proteasome inhibitor and an immunomodulatory agent, and whose disease remained refractory to these treatments.

This initial nod was based on data from the Phase 2 SIRIUS trial, which demonstrated meaningful response rates in a heavily pretreated patient population. The accelerated approval pathway allowed patients earlier access to this innovative therapy while Janssen continued to collect confirmatory data.

Expanded Approvals and Combination Therapies

Following the initial approval, Darzalex quickly expanded its role in multiple myeloma treatment

through subsequent FDA approvals:

- **May 2016:** Darzalex received full FDA approval for use as a monotherapy in patients with multiple myeloma who had received at least three prior lines of therapy, confirming the clinical benefit shown in earlier trials.

- **November 2016:** The FDA approved Darzalex in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma, based on the results of the POLLUX trial. This combination showed significant improvements in progression-free survival compared to standard treatment.

- **November 2017:** Darzalex was approved in combination with bortezomib and dexamethasone after the CASTOR trial demonstrated enhanced efficacy in relapsed or refractory multiple myeloma.

These approvals marked a shift in the darzalex fda approval history, moving from monotherapy to combination regimens, which have since become standard practice in managing multiple myeloma.

Frontline Treatment Approvals

The evolution of Darzalex did not stop at relapsed disease. In 2018 and beyond, the FDA recognized its potential in newly diagnosed multiple myeloma patients:

- **May 2018:** Darzalex was approved in combination with bortezomib, melphalan, and prednisone (VMP) for newly diagnosed patients who were ineligible for stem cell transplant, following the ALCYONE trial results.

- **March 2020:** The FDA approved Darzalex in combination with lenalidomide and dexamethasone for newly diagnosed transplant-ineligible patients, based on findings from the MAIA study.

- **November 2020:** Darzalex received approval for use with bortezomib, thalidomide, and dexamethasone for newly diagnosed, transplant-eligible patients, expanding its reach across all multiple myeloma patient groups.

These approvals underscore the FDA’s recognition of Darzalex’s efficacy and safety profile in diverse treatment settings.

Darzalex FDA Approval History in Other Indications

While Darzalex is primarily known for multiple myeloma, its FDA approval history also includes other hematologic malignancies:

- **Light chain (AL) amyloidosis:** In early 2021, Darzalex was granted accelerated approval for treating AL amyloidosis in combination with other agents, representing a new therapeutic option for this rare disease.

- **Smoldering multiple myeloma and other plasma cell disorders:** Ongoing clinical trials are evaluating Darzalex in earlier stages of disease, which may lead to future FDA approvals and further

expand its clinical utility.

FDA’s Role in Accelerating Access

Throughout Darzalex’s approval journey, the FDA employed various regulatory pathways to facilitate timely patient access:

- **Accelerated Approval:** Enabled early approval based on surrogate endpoints with the requirement for post-marketing confirmatory trials.

- **Priority Review:** Shortened the review time due to the drug’s potential to provide significant improvements in treatment.

- **Breakthrough Therapy Designation:** Granted to Darzalex early in its development, helping expedite review and development processes.

These designations reflect the FDA’s commitment to balancing rapid access to promising therapies with ensuring safety and efficacy.

Impact of Darzalex’s FDA Approvals on Multiple Myeloma Treatment

The darzalex fda approval history is not just a timeline of regulatory events; it represents a paradigm shift in how multiple myeloma is treated. Before Darzalex, treatment options for relapsed or refractory patients were limited and often associated with poor outcomes. Darzalex introduced a new class of targeted therapy that harnessed the immune system, setting the stage for subsequent immunotherapies in hematologic cancers.

Oncologists now routinely use Darzalex in combination regimens, leading to longer progression-free survival and improved quality of life for patients. Furthermore, its approval in frontline settings has helped patients achieve deeper responses earlier, which is crucial for long-term disease management.

Considerations for Patients and Healthcare Providers

Understanding the darzalex fda approval history is valuable not only for healthcare professionals but also for patients navigating treatment decisions. Here are some key insights:

- **Treatment sequencing:** Darzalex’s approvals across multiple lines of therapy provide flexibility in designing personalized treatment plans.

- **Administration routes:** Initially available only as an intravenous infusion, Darzalex now also has a subcutaneous formulation approved by the FDA, offering convenience and reduced infusion times.

- **Side effect management:** Familiarity with the drug’s safety profile, including infusion-related

reactions and immunosuppression risks, is critical for optimizing patient care.

The Future of Darzalex and Ongoing Developments

The darzalex fda approval history is still being written. Research continues to explore novel combinations, earlier intervention strategies, and use in other plasma cell disorders. Additionally, biosimilars and next-generation anti-CD38 antibodies are under development, promising to broaden treatment options further.

As clinical trials progress and real-world evidence accumulates, the FDA’s approval framework may adapt to incorporate these advances, ensuring patients benefit from the latest scientific breakthroughs.

In summary, the darzalex fda approval history highlights a remarkable journey from a novel monoclonal antibody to a multi-indication, multi-combination therapeutic agent that has reshaped multiple myeloma care. Its story exemplifies the dynamic interplay between biomedical innovation, regulatory science, and patient-centered medicine, providing hope and improved outcomes for those affected by challenging blood cancers.

Frequently Asked Questions

When was Darzalex first approved by the FDA?

Darzalex (daratumumab) was first approved by the FDA on November 16, 2015, for the treatment of multiple myeloma in patients who have received at least three prior lines of therapy.

What was the initial FDA-approved indication for Darzalex?

The initial FDA approval of Darzalex was for use as a monotherapy in patients with multiple myeloma who had received at least three prior therapies, including a proteasome inhibitor and an immunomodulatory agent, and who had demonstrated disease progression on the last therapy.

Has the FDA expanded the indications for Darzalex since its initial approval?

Yes, the FDA has expanded Darzalex's indications multiple times to include use in combination therapies for newly diagnosed multiple myeloma, both transplant-eligible and ineligible patients, and for treatment of light chain amyloidosis.

What are some notable FDA approval milestones in Darzalex's

history?

Notable milestones include its initial approval in 2015 as a monotherapy for relapsed multiple myeloma, approval in 2018 for use in combination with other agents for newly diagnosed patients, and in 2021 for treatment of light chain amyloidosis.

Is Darzalex approved for use in combination therapies by the FDA?

Yes, the FDA has approved Darzalex for use in combination with other drugs such as lenalidomide, bortezomib, and dexamethasone for the treatment of multiple myeloma in various settings.

What is the significance of Darzalex's FDA approval for patients with multiple myeloma?

Darzalex's FDA approval has provided a novel therapeutic option targeting CD38, significantly improving treatment outcomes and survival rates for multiple myeloma patients, especially those with relapsed or newly diagnosed disease.

Additional Resources

Darzalex FDA Approval History: A Detailed Review of Its Regulatory Milestones and Clinical Impact

darzalex fda approval history offers a compelling narrative of a breakthrough monoclonal antibody therapy that has significantly altered the treatment landscape for multiple myeloma. Since its initial clearance, Darzalex (daratumumab) has undergone a series of regulatory expansions, reflecting growing clinical evidence and a broader understanding of its therapeutic potential. This article explores the chronological development of Darzalex's FDA approvals, analyzing the clinical trials, indications, and regulatory decisions that have shaped its journey.

Overview of Darzalex and Its Mechanism of Action

Before diving into the FDA approval timeline, it is essential to understand what Darzalex is and how it functions. Darzalex is a human monoclonal antibody targeting CD38, a cell surface protein highly expressed on multiple myeloma cells. By binding to CD38, Darzalex initiates immune-mediated mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, leading to myeloma cell death. This novel mechanism differentiates it from traditional chemotherapy and has contributed to its rapid adoption in hematology-oncology.

The Genesis of Darzalex FDA Approval History

Initial FDA Approval in 2015

The first FDA approval for Darzalex came in November 2015, marking a pivotal moment in multiple myeloma treatment. The initial indication was for patients with multiple myeloma who had received at least three prior therapies, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), and whose disease was refractory to these treatments. This accelerated approval was based on data from clinical trials demonstrating Darzalex's efficacy as a monotherapy, showcasing a significant overall response rate (ORR) in heavily pretreated patients.

The phase 2 SIRIUS trial was instrumental in this decision, reporting an ORR of approximately 29% in a population with limited options. This milestone approval represented the first CD38-targeted therapy to enter the market, setting a precedent for subsequent immunotherapies.

Expansion to Combination Therapies (2016-2018)

Following its initial monotherapy approval, Darzalex's FDA indications expanded rapidly as new clinical trial data emerged supporting its use in combination regimens. In 2016, the FDA approved Darzalex in combination with lenalidomide and dexamethasone (Rd) for patients with multiple myeloma who had received at least one prior therapy. This was based on the phase 3 POLLUX trial, which demonstrated a remarkable improvement in progression-free survival (PFS) compared to Rd alone.

Similarly, in 2017, Darzalex received approval in combination with bortezomib and dexamethasone (Vd) for patients with relapsed or refractory multiple myeloma, supported by the CASTOR trial results. These combination approvals significantly broadened Darzalex’s clinical utility and cemented its role as a backbone therapy in multiple myeloma.

First-Line and Newly Diagnosed Patient Approvals

The FDA’s confidence in Darzalex grew as evidence accumulated for its efficacy in earlier stages of multiple myeloma. In 2018, Darzalex was approved in combination with bortezomib, melphalan, and prednisone (VMP) for newly diagnosed patients ineligible for stem cell transplant, based on the ALCYONE trial. This marked Darzalex's entry into front-line therapy, an important evolution considering the aggressive nature of newly diagnosed disease.

The following year, in 2019, Darzalex in combination with lenalidomide and dexamethasone was approved for newly diagnosed transplant-eligible patients, supported by the phase 3 CASSIOPEIA trial. These approvals underscored Darzalex’s expanding role across multiple treatment settings, from relapsed to newly diagnosed cases.

Recent Developments and Subcutaneous Formulation Approval

Subcutaneous Darzalex Approval in 2020

A significant advancement in Darzalex's FDA approval history was the 2020 clearance of a subcutaneous (SC) formulation. The SC version, administered as a fixed-dose injection, offers several advantages over the original intravenous (IV) infusion, including reduced administration time and improved patient convenience.

The FDA approval was based on data from the COLUMBA trial, which demonstrated comparable efficacy and safety profiles between SC and IV formulations. This innovation addressed a critical patient need by minimizing infusion-related reactions and reducing chair time, enhancing treatment adherence in both clinical and outpatient settings.

Ongoing Expansions and Investigational Uses

Beyond multiple myeloma, Darzalex is being studied in other hematologic malignancies, including light chain (AL) amyloidosis and certain types of lymphoma. While these indications have not yet received FDA approval, ongoing clinical trials continue to shape the future potential of Darzalex. The FDA has granted breakthrough therapy designations and orphan drug status for some of these uses, reflecting the therapeutic promise.

Analyzing the Impact of Darzalex FDA Approval History

The sequential FDA approvals of Darzalex highlight a trend toward personalized and targeted cancer therapies. Darzalex's journey from a salvage monotherapy to a front-line combination regimen exemplifies how regulatory agencies adapt to evolving clinical evidence. The drug's integration into multiple treatment protocols has improved outcomes for many patients, including extended progression-free survival and better overall response rates.

From a regulatory perspective, Darzalex's approvals leveraged accelerated pathways and breakthrough therapy designations, underscoring the FDA's willingness to expedite access to promising therapies addressing unmet medical needs. Moreover, the approval of a subcutaneous formulation illustrates a growing emphasis on patient-centered drug delivery innovations.

Comparisons with Other Multiple Myeloma Therapies

Within the expanding multiple myeloma market, Darzalex competes and complements other agents such as elotuzumab (Empliciti) and carfilzomib (Kyprolis). Its unique CD38 target differentiates it mechanistically, while its favorable safety profile and adaptability in various regimens contribute to its widespread adoption.

Unlike some chemotherapies associated with significant toxicities, Darzalex's infusion-related reactions are generally manageable, especially with the SC formulation. This balance of efficacy and tolerability has helped it become a cornerstone drug for hematologists.

Challenges and Considerations

Despite its successes, Darzalex's FDA approval history also reflects challenges common to biologic therapies. The cost of treatment remains high, posing access and reimbursement issues for healthcare systems and patients. Additionally, resistance mechanisms and relapses necessitate ongoing research into combination strategies and next-generation CD38-targeting drugs.

Moreover, infusion-related reactions, although reduced with SC administration, require careful monitoring during initial doses. Patient selection and management protocols are critical to optimizing outcomes.

Conclusion: Darzalex's Regulatory Journey and Clinical Significance

The darzalex fda approval history is a testament to the rapid evolution of cancer therapeutics and regulatory agility. From its initial breakthrough status in 2015 to its current role in front-line therapy and improved formulations, Darzalex exemplifies innovation in monoclonal antibody development for hematologic cancers. Its approvals have been grounded in robust clinical trial data, reflecting a commitment to evidence-based medicine.

As ongoing trials explore new indications and combination regimens, Darzalex's role is expected to further expand. Its approval history serves not only as a timeline of regulatory milestones but also as a case study in how targeted therapies can transform patient care in oncology.

Darzalex Fda Approval History

darzalex fda approval history: The APRN and PA's Complete Guide to Prescribing Drug Therapy 2024 Mari J. Wirfs, 2024-03-19 An unrivaled reference tool for advanced practice providers and students in clinical practice settings This concise and easy-to-read drug therapy prescribing reference provides critical information for advanced practice nurses and physician assistants in clinical practice settings who are involved in the primary care management of patients with acute, episodic, and chronic health problems, life-altering and life-threatening diseases, and needs for health promotion and disease prevention. Interspersed with clinically useful information, such as monitored laboratory values, patient teaching points, and safety information, this reference draws upon data taken directly from FDA-approved drug labels and patient medication guides, and is organized by diagnosis rather than by drug classification, to provide advanced practice practitioners with the comprehensive, concise, and up-to-date information on drug therapies that they need to help achieve positive outcomes in their daily practice. The first section of this book presents drug treatment regimens for over 700 clinical diagnoses, listed alphabetically by generic name, followed by important information required for prescription decision-making. The second section provides additional information on treatment, organized in a convenient table format. An alphabetical cross-reference index of drugs allows for easy identification of alternate drug names and their location within the text. New to this Edition: Information on over 100 new diagnoses and over 100 new generic drugs indicated for the treatment of quality of life-altering and life-threatening

conditions such as chronic kidney disease, genetic diseases, mesothelioma, MS, metastatic cancers, and rare diseases. Updates on drugs used for site-specific cancers, mental health issues, and commonly diagnosed diseases such as diabetes and asthma. Details on new drug approvals including indications, treatment regimens, adverse reactions, drug-drug interactions, warnings and precautions, and use in special populations Key Features: Provides new drug treatment regimens for drugs that are first in class, novel drugs, orphan drugs, new drugs with breakthrough or fast track designation and drugs with new indications and expanded social populations. Includes drug prescribing information on diseases prevalent outside of North America, including endemic diseases with known transmission and treatment interventions. Serves advanced practice providers across the United States and internationally. Consistent with approvals and recommendations for use by the FDA.

darzalex fda approval history: Pharmacotherapy Principles and Practice, Sixth Edition Marie A. Chisholm-Burns, Terry L. Schwinghammer, Patrick M. Malone, Jill M. Kolesar, Kelly C Lee, P. Brandon Bookstaver, 2022-02-04 All the main concepts from the landmark Pharmacotherapy: A Pathophysiologic Approach—distilled down to a concise, clinically focused, full-color resource Providing a solid evidence-based approach, Pharmacotherapy Principles & Practice, Sixth Edition explains how to design, implement, monitor, and evaluate medication therapy. You'll gain an in-depth understanding of the underlying principles of the pharmacotherapy of disease—and their practical application. Pharmacotherapy Principles & Practice includes chapters on geriatrics, pediatrics, and palliative care. Each of the subsequent disease-based chapters covers disease epidemiology, etiology, pathophysiology, clinical presentation and diagnosis, nonpharmacologic therapy, followed by therapeutic recommendations for medication selection, desired outcomes, dosing, and patient monitoring. Features Chapters are written/reviewed by pharmacists, NPs, PAs, and physicians considered authorities in their fields Learning objectives with associated content identified with a margin rule Disorder-based organization makes finding answers quick and easy Surveys the full range of organ system disorders treated in pharmacy practice Knowledge-building boxed features within chapters cover Clinical Presentation & Diagnosis, Patient Encounters, and Patient Care and Monitoring Guidelines Standardized chapter format Laboratory values are presented in conventional and Systemé International units Key concepts are indicated in text with numbered icons Content on cultural competency Glossary Online Learning Center

darzalex fda approval history: The FDA and Psychiatric Drugs Joan Esherick, 2014 Imagine taking a medication meant to heal you only to discover that the drug rotted your bones, made your teeth fall out, and filled you with a radioactive element called radium. Pittsburgh industrialist Eben Byers didn't have to imagine. It happened to him, and he died as a result.

darzalex fda approval history: The FDA & Psychiatric Drugs Joan Esherick, 2014-09-02 Imagine taking a medication meant to heal you only to discover that the drug rotted your bones, made your teeth fall out, and filled you with a radioactive element called radium. Pittsburgh industrialist Eben Byers didn't have to imagine. It happened to him, and he died as a result. Mr. Byers fell victim to patent medicines sold in the early twentieth century. Patent medicine quackery and other medical tragedies prompted the United States government to form an agency that could protect patients and consumers from mislabeled or dangerous medicines, cosmetics, and foods. That agency is the U.S. Food and Drug Administration (FDA). Most drugs and medical treatments sold in North America today, including drugs used to treat psychological disorders, are regulated by this consumer protection agency. Many people diagnosed with depression, panic attacks, schizophrenia, ADHD, and other psychological disorders lead normal lives because they are treated with psychiatric drugs approved by the FDA. But what are psychiatric drugs? Where do they come from? How do they work? What does it take for the FDA to approve them? Why do we have the FDA? Perhaps most important, does FDA approval guarantee safety? Loaded with case studies and user-friendly illustrations, this readable text answers these and other questions as it examines a brief history of mental disorders and their treatment. In its pages, you will learn about the origins of the FDA, the FDA drug approval process, the structure and chemistry of the brain, psychiatric drugs and how

they work, adverse reactions, and alternative treatments. Come learn about the drug approval process. Next time you reach into your medicine cabinet, you'll be glad you did.

darzalex fda approval history: How the Food and Drug Administration (FDA) Approves Drugs and Regulates Their Safety and Effectiveness Susan Thaul, 2012-11-05 The Food and Drug Admin. (FDA) is a regulatory agency within the Dept. of Health and Human Services (HHS). A key responsibility is to regulate the safety and effectiveness of drugs sold in the U.S. FDA divides that responsibility into two phases: preapproval (premarket) and postapproval (postmarket). FDA reviews manufacturers' applications to market drugs in the U.S.; a drug may not be sold unless it has FDA approval. The agency continues its oversight of drug safety and effectiveness as long as the drug is on the market. Beginning with the Food and Drugs Act of 1906, Congress has incrementally refined and expanded FDA's responsibilities regarding drug approval and regulation. Contents of this report: Legislative History of Drug Regulation; How FDA Approves New Drugs; How FDA Regulates Approved Drugs. Figures and tables. This is a print on demand report.

darzalex fda approval history: Generic and Innovator Drugs Donald O. Beers, Kurt R. Karst, 2013-05-22 Completely updated, the new Eighth Edition of Generic and Innovator Drugs: A Guide to FDA Approval Requirements provides indispensable and practical insights into the FDA approval process. Youand’ll find comprehensive coverage of: Abbreviated new drug applications 505(b)(2) new drug applications Delaying approval of competing products FDA approval of biologic drugs No other book can cover the drug approval process as thoroughly, answering important questions like these: What is required to extend the patent of an FDA-approved product? When must a generic manufacturer notify the innovator manufacturer when submitting an ANDA or 505(b)(2) application? When does the FDA delay approvals because of patent claims, and when does it ignore patents? How can one challenge an FDA exclusivity decision? When can a manufacturer safely sell a drug without prior FDA approval? In what circumstances can a generic manufacturer obtain FDA permission to file an ANDA for a variant of an existing drug? When will the FDA waive or reduce prescription drug user fees? How can a company or an individual avoid debarment? What steps are necessary to comply with the FDAand’s Fraud Policy? When and how can a drug company take advantage of FDA accelerated approval procedures? What are the labeling requirements for exporting approved drugs? How have the changes made by the FDA Safety and Innovation Act, including the Prescription Drug User Fee Act, the Generic Drug User Fee Amendments and the Biosimilars User Fee Act, and the Generating Antibiotic Incentives Now Act affected the overall statutory scheme? Generic and Innovator Drugs: A Guide to FDA Approval Requirements, Eighth Edition provides step-by-step guidance of the approval process and expert interpretation of: The Hatch-Waxman Act (Drug Price Competition and Patent Restoration Act) The Medicare Prescription Drug, Improvement, and Modernization Act The Food and Drug Administration Modernization Act The FDA Export Reform and Enhancement Act The Biologics Price Competition and Innovation Act And more! AUTHOR NOTE Donald O. Beersand’ contributions to this publication were completed before he rejoined the Food and Drug Administration. He has had no part in writing and revising this Eighth Edition.

darzalex fda approval history: How FDA Approves Drugs and Regulates Their Safety and Effectiveness Susan Thaul, 2012-07-03 Update: On June 20, 2012, the House of Representatives passed, by voice vote and under suspension of the rules, S. 3187 (EAH), the Food and Drug Administration Safety and Innovation Act, as amended. This bill would reauthorize the FDA prescription drug and medical device user fee programs (which would otherwise expire on September 30, 2012), create new user fee programs for generic and biosimilar drug approvals, and make other revisions to other FDA drug and device approval processes. It reflects bicameral compromise on earlier versions of the bill (S. 3187 [ES], which passed the Senate on May 24, 2012, and H.R. 5651 [EH], which passed the House on May 30, 2012). The following CRS reports provide overview information on FDA's processes for approval and regulation of drugs: CRS Report R41983, How FDA Approves Drugs and Regulates Their Safety and Effectiveness, by Susan Thaul. CRS Report RL33986, FDA's Authority to Ensure That Drugs Prescribed to Children Are Safe and

Effective, by Susan Thaul. CRS Report R42130, FDA Regulation of Medical Devices, by Judith A. Johnson. CRS Report R42508, The FDA Medical Device User Fee Program, by Judith A. Johnson. (Note: The rest of this report has not been updated since September 1, 2011.) The Food and Drug Administration (FDA) is a regulatory agency within the Department of Health and Human Services. A key responsibility is to regulate the safety and effectiveness of drugs sold in the United States. FDA divides that responsibility into two phases: preapproval (premarket) and postapproval (postmarket). FDA reviews manufacturers' applications to market drugs in the United States; a drug may not be sold unless it has FDA approval. The agency continues its oversight of drug safety and effectiveness as long as the drug is on the market. Beginning with the Food and Drugs Act of 1906, Congress has incrementally refined and expanded FDA's responsibilities regarding drug approval and regulation. The progression to drug approval begins before FDA involvement. First, basic scientists work in the laboratory and with animals; second, a drug or biotechnology company develops a prototype drug. That company must seek and receive FDA approval, by way of an investigational new drug (IND) application, to test the product with human subjects. Those tests, called clinical trials, are carried out sequentially in Phase I, II, and III studies, which involve increasing numbers of subjects. The manufacturer then compiles the resulting data and analysis in a new drug application (NDA). FDA reviews the NDA with three major concerns: (1) safety and effectiveness in the drug's proposed use; (2) appropriateness of the proposed labeling; and (3) adequacy of manufacturing methods to assure the drug's identify, strength, quality, and identity. The Federal Food, Drug, and Cosmetic Act (FFDCA) and associated regulations detail the requirements at each step. FDA uses a few special mechanisms to expedite drug development and the review process when a drug might address an unmet need or a serious disease or condition. Those mechanisms include accelerated approval, animal efficacy approval, fast track applications, and priority review. Once a drug is on the U.S. market (following FDA approval of the NDA), FDA continues to address drug production, distribution, and use. Its activities, based on ensuring drug safety and effectiveness, address product integrity, labeling, reporting of research and adverse events, surveillance, drug studies, risk management, information dissemination, off-label use, and directto- consumer advertising, all topics in which Congress has traditionally been interested. FDA seeks to ensure product integrity through product and facility registration; inspections; chain-of-custody documentation; and technologies to protect against counterfeit, diverted, subpotent, adulterated, misbranded, and expired drugs.~

darzalex fda approval history: Protecting America's Health Philip J. Hilts, 2003-01-01 Provides a detailed history of the Food and Drug Administration as it evolved into America's most important regulatory agency, designed to protect the nation from hazardous medicines and food products.

Related to darzalex fda approval history

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Learn about adult treatment with DARZALEX® and DARZALEX FASPRO®. See Full Prescribing & Safety Information

How is Treatment Given - DARZALEX FASPRO® (daratumumab Learn how treatment is given across both DARZALEX® and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj). See Full Prescribing & Safety Information

Preparing For Treatment | DARZALEX® & DARZALEX FASPRO® Find out what you can expect before, during, and after treatment with DARZALEX® and DARZALEX FASPRO®. See Full Prescribing & Safety Information

Side Effects | DARZALEX® & DARZALEX FASPRO® (daratumumab See DARZALEX FASPRO® side effects, including reactions to the injection. See full Prescribing and Safety Information

About DARZALEX® & DARZALEX FASPRO® (daratumumab and DARZALEX FASPRO ® and DARZALEX ® are prescription medicines used alone or in combination with one or more treatments for adults with a rare form of blood cancer called

What is multiple myeloma? - DARZALEX FASPRO® (daratumumab DARZALEX FASPRO ®

can decrease white blood cell counts, which help fight infections, and blood cells called platelets, which help to clot blood. Decreases in blood cell counts are

Patient & Care Partner Support | DARZALEX® & DARZALEX Find patient and care partner support for DARZALEX® & DARZALEX FASPRO® including paying for treatment, patient support, and more. See Full Prescribing & Safety Info

Clinical Results | DARZALEX® & DARZALEX FASPRO® See DARZALEX® & DARZALEX FASPRO® clinical results, including additional studies for newly diagnosed & relapsed or refractory patients. See Full Prescribing & Safety Info

SELECT IMPORTANT SAFETY INFORMATION - DARZALEX In a clinical study, patients on DARZALEX FASPRO® experienced results comparable to the intravenous (IV) formulation of DARZALEX® (daratumumab) in treating multiple myeloma

FAQs - DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) DARZALEX FASPRO® and DARZALEX® were both studied as combination therapies with other medicines and as monotherapies (by themselves). You can find information about each of the

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Learn about adult treatment with DARZALEX® and DARZALEX FASPRO®. See Full Prescribing & Safety Information

How is Treatment Given - DARZALEX FASPRO® (daratumumab and Learn how treatment is given across both DARZALEX® and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj). See Full Prescribing & Safety Information

Preparing For Treatment | DARZALEX® & DARZALEX FASPRO® Find out what you can expect before, during, and after treatment with DARZALEX® and DARZALEX FASPRO®. See Full Prescribing & Safety Information

Side Effects | DARZALEX® & DARZALEX FASPRO® (daratumumab See DARZALEX FASPRO® side effects, including reactions to the injection. See full Prescribing and Safety Information

About DARZALEX® & DARZALEX FASPRO® (daratumumab and DARZALEX FASPRO ® and DARZALEX ® are prescription medicines used alone or in combination with one or more treatments for adults with a rare form of blood cancer called

What is multiple myeloma? - DARZALEX FASPRO® (daratumumab DARZALEX FASPRO ® can decrease white blood cell counts, which help fight infections, and blood cells called platelets, which help to clot blood. Decreases in blood cell counts are

Patient & Care Partner Support | DARZALEX® & DARZALEX Find patient and care partner support for DARZALEX® & DARZALEX FASPRO® including paying for treatment, patient support, and more. See Full Prescribing & Safety Info

Clinical Results | DARZALEX® & DARZALEX FASPRO® See DARZALEX® & DARZALEX FASPRO® clinical results, including additional studies for newly diagnosed & relapsed or refractory patients. See Full Prescribing & Safety Info

SELECT IMPORTANT SAFETY INFORMATION - DARZALEX In a clinical study, patients on DARZALEX FASPRO® experienced results comparable to the intravenous (IV) formulation of DARZALEX® (daratumumab) in treating multiple myeloma

FAQs - DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) DARZALEX FASPRO® and DARZALEX® were both studied as combination therapies with other medicines and as monotherapies (by themselves). You can find information about each of the

Related to darzalex fda approval history

FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen (Cure Today1mon) The FDA declined approval of Darzalex Faspro for newly diagnosed, transplant-ineligible multiple myeloma in its current form. A complete response letter (CRLs) was issued by the U.S. Food and Drug

FDA Gives Complete Response Letter for Darzalex Faspro Quadruplet Regimen (Cure Today1mon) The FDA declined approval of Darzalex Faspro for newly diagnosed, transplant-ineligible multiple myeloma in its current form. A complete response letter (CRLs) was issued by the

U.S. Food and Drug

Daratumumab Approved for Multiple Myeloma in US (Medscape9y) A novel option is now available for patients with multiple myeloma who have tried at least three other drug therapies — the first monoclonal antibody for use in this disease, daratumumab (Darzalex,

Daratumumab Approved for Multiple Myeloma in US (Medscape9y) A novel option is now available for patients with multiple myeloma who have tried at least three other drug therapies — the first monoclonal antibody for use in this disease, daratumumab (Darzalex,

J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications (Hosted on MSN3mon) J&J JNJ announced that the EMA's Committee for Medicinal Products for Human Use ("CHMP") recommended granting label expansion to its two key products, Darzalex and Imbruvica, across separate new

J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications (Hosted on MSN3mon) J&J JNJ announced that the EMA's Committee for Medicinal Products for Human Use ("CHMP") recommended granting label expansion to its two key products, Darzalex and Imbruvica, across separate new

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma (KTLA2mon) SAN DIEGO, July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma (KTLA2mon) SAN DIEGO, July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European

Related Articles

- v for vendetta graphic novel
- age specific groups are used as practice care
- the golden gate vikram seth

Back to Home